glp 1 drugs and parkinson's disease Are we measuring the wrong primary outcome for GLP-1 for Parkinson's? Spoiler alert: the pooled data suggests we should pivot away from a motor outcome. Should we think cognitive, autonomic, sleep GLP-1 agonists in Parkinson's disease:

L-Carnitine improves the efficiency of energy turn over by mobilizing fat stores, making glucose readily available in the cells to make energy

Magnesium may help to maintain the function of the heart, muscles, and nervous system

Food supplements are not intended to replace a balanced and varied diet

By targeting the root cause of discoloration, it gradually lightens existing spots and prevents new ones from forming, resulting in a more even and radiant complexion

La carnitina, facilitando la trasformazione del grasso in energia, sembrerebbe favorire la combustione dei grassi durante l'esercizio fisico

Some patients notice sleep changes earlier, while body composition changes tend to develop more gradually